Search

Your search keyword '"Shiv K. Gupta"' showing total 237 results

Search Constraints

Start Over You searched for: Author "Shiv K. Gupta" Remove constraint Author: "Shiv K. Gupta"
237 results on '"Shiv K. Gupta"'

Search Results

1. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

2. Editorial: Patient-derived tumor models for drug development

3. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

4. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b

5. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

7. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas

8. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

9. Synthesis and Antifungal Activities of 5-(o-Hydroxy phenyl)-2-[4'aryl-3'chloro-2'azetidinon-1-yl]-1,3,4-thiadiazole

10. Data from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

11. Figure S1 from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

12. Supplementary Information from Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

13. Data from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

14. Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

15. Supplementary Figure S5 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

16. Supplementary Methods and Legend from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

17. Supplementary Table 1 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

18. Data from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

19. Supplementary Tables 1 through 7 and Supplementary Figures 1 through 6 from DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme

20. Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

22. Supplementary Figure 1 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

23. Data from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

24. Data from DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme

26. Supplementary Table 2 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

27. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts

28. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

29. Study of defect production in neutron irradiated Cu, Ni and Pb using positron annihilation spectroscopy (PAS)

30. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors

31. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma

32. Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor

33. Abstract 2598: AZD1390 radio-sensitizes p53-mutant GBM via disrupting homology directed DNA repair

34. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma

35. EXTH-01. INHIBITION OF DNA-PKcs BY M3814 POTENTIATES EFFICACY OF IONIZING RADIATION IN PATIENT-DERIVED XENOGRAFTS OF MELANOMA BRAIN METASTASES

36. Determinants of long-term quality of life outcomes following radical cystectomy and orthotopic neobladder

37. Robotic modified Sugarbaker intraperitoneal onlay graft hernioplasty for ileal conduit urinary diversion associated parastomal hernia

38. Robotic salvage cystectomy post radiotherapy: It’s feasible

39. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of

40. Variation in cosmic ray flux during Solar Eclipse on 21 June, 2020 at Jaipur, India

41. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

42. Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

43. Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex

44. Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells

46. Targeted Therapies for Glioblastoma: A Critical Appraisal

47. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

48. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas

49. Robot assisted video endoscopic inguinal lymph node dissection in carcinoma penis with palpable inguinal lymphadenopathy: Our technique and long term functional and oncological outcomes

50. Anionic conduction mediated giant n-type Seebeck coefficient in doped Poly(3-hexylthiophene) free-standing films

Catalog

Books, media, physical & digital resources